AbbVie announces plans to acquire Apogee Therapeutics, aiming to deepen its immunology portfolio and broaden its pipeline for inflammatory and immune-related diseases. According to the announcement, the proposed deal would add multiple assets targeting areas that include dermatologic and respiratory conditions, alongside other related inflammatory and immunological diseases. Apogee’s lead program is zumilokibart (APG777), described as a late-stage, half-life extended monoclonal antibody. The companies characterize the acquisition as a way to expand treatment options and advance development across immunology-focused therapeutic programs.
The provided materials do not include details on purchase price, deal timeline, regulatory approvals, or expected closing conditions, nor do they specify the trial phases or results for the mentioned assets beyond noting that the lead asset is late-stage. The announcement reflects AbbVie’s stated intent to strengthen its pipeline by bringing in Apogee’s immunology-focused development programs.
